PMID- 29446854
OWN - NLM
STAT- MEDLINE
DCOM- 20180416
LR  - 20210109
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 109
IP  - 4
DP  - 2018 Apr
TI  - Overexpression of interleukin-35 in intrahepatic cholangiocarcinoma is a 
      prognostic indicator after curative resection.
PG  - 1195-1206
LID - 10.1111/cas.13535 [doi]
AB  - Interleukin-35 (IL-35) is implicated in tumorigenesis, but its exact impact on 
      intrahepatic cholangiocarcinoma (ICC) is not clear. The aim of the present study 
      was to explore the specific effect of IL-35 on patient prognosis. Additionally, 
      we formulated an effective prognostic nomogram for ICC patients after curative 
      resection. Immunohistochemistry was applied to explore IL-35 expression as well 
      as IL-35 receptor (IL-35R) in 102 ICC patients. Results showed that IL-35 was 
      highly expressed in ICC tumor tissues and was positively associated with lymph 
      node metastasis (LNM), TNM stage and vascular invasion and was an independent 
      prognostic factor for patients' overall survival (OS) and recurrence-free 
      survival (RFS). High expression of IL-35R (gp130 and IL-12Rbeta2) was also observed 
      in ICC cancer tissues, but only gp130 was an independent prognostic factor for OS 
      and RFS and was indispensable in IL-35-mediated ICC clinical prognosis. The 
      nomogram comprising carcinoembryonic antigen, LNM, IL-35 and gp130 expression 
      achieved better predictive accuracy compared with TNM stage for OS. Our data 
      support that high IL-35 expression correlates with ICC aggressiveness and emerges 
      as a valuable biomarker for evaluating ICC progression and prognosis in clinical 
      work.
CI  - (c) 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd 
      on behalf of Japanese Cancer Association.
FAU - Zhang, Mei-Xia
AU  - Zhang MX
AUID- ORCID: 0000-0003-0978-4721
AD  - Liver Cancer Institute and Zhongshan Hospital of Fudan University, Shanghai, 
      China.
FAU - Gan, Wei
AU  - Gan W
AD  - Liver Cancer Institute and Zhongshan Hospital of Fudan University, Shanghai, 
      China.
FAU - Jing, Chu-Yu
AU  - Jing CY
AD  - Liver Cancer Institute and Zhongshan Hospital of Fudan University, Shanghai, 
      China.
FAU - Zheng, Su-Su
AU  - Zheng SS
AD  - Liver Cancer Institute and Zhongshan Hospital of Fudan University, Shanghai, 
      China.
FAU - Zhang, Juan
AU  - Zhang J
AD  - Liver Cancer Institute and Zhongshan Hospital of Fudan University, Shanghai, 
      China.
FAU - Shen, Hu-Jia
AU  - Shen HJ
AD  - Liver Cancer Institute and Zhongshan Hospital of Fudan University, Shanghai, 
      China.
FAU - Xu, Xin
AU  - Xu X
AD  - Liver Cancer Institute and Zhongshan Hospital of Fudan University, Shanghai, 
      China.
FAU - Lin, Jia-Jia
AU  - Lin JJ
AD  - Liver Cancer Institute and Zhongshan Hospital of Fudan University, Shanghai, 
      China.
FAU - Zhang, Bo-Heng
AU  - Zhang BH
AD  - Liver Cancer Institute and Zhongshan Hospital of Fudan University, Shanghai, 
      China.
AD  - Center for Evidence-Based Medicine, Fudan University, Shanghai, China.
FAU - Qiu, Shuang-Jian
AU  - Qiu SJ
AD  - Liver Cancer Institute and Zhongshan Hospital of Fudan University, Shanghai, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20180325
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (IL36A protein, human)
RN  - 0 (Interleukin-1)
RN  - 0 (Interleukins)
RN  - 0 (Receptors, Interleukin-12)
RN  - 133483-10-0 (Cytokine Receptor gp130)
SB  - IM
MH  - Bile Duct Neoplasms/*metabolism/pathology
MH  - Bile Ducts, Intrahepatic/*metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cholangiocarcinoma/*metabolism/pathology
MH  - Cytokine Receptor gp130/metabolism
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Interleukin-1/metabolism
MH  - Interleukins/*metabolism
MH  - Lymphatic Metastasis/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/metabolism/pathology
MH  - Neoplasm Staging/methods
MH  - Prognosis
MH  - Receptors, Interleukin-12/metabolism
MH  - Retrospective Studies
PMC - PMC5891208
OTO - NOTNLM
OT  - IL-12Rbeta2
OT  - IL-35
OT  - gp130
OT  - intrahepatic cholangiocarcinoma
OT  - nomogram
EDAT- 2018/02/16 06:00
MHDA- 2018/04/17 06:00
PMCR- 2018/04/01
CRDT- 2018/02/16 06:00
PHST- 2017/12/12 00:00 [received]
PHST- 2018/02/08 00:00 [revised]
PHST- 2018/02/10 00:00 [accepted]
PHST- 2018/02/16 06:00 [pubmed]
PHST- 2018/04/17 06:00 [medline]
PHST- 2018/02/16 06:00 [entrez]
PHST- 2018/04/01 00:00 [pmc-release]
AID - CAS13535 [pii]
AID - 10.1111/cas.13535 [doi]
PST - ppublish
SO  - Cancer Sci. 2018 Apr;109(4):1195-1206. doi: 10.1111/cas.13535. Epub 2018 Mar 25.